A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3'-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Copanlisib (Primary) ; Paclitaxel
- Indications Male breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 06 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.